Longitudinal kinetics of RBD+ antibodies in COVID-19 recovered patients over 14 months.
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
12
10
2021
accepted:
03
05
2022
revised:
15
06
2022
pubmed:
4
6
2022
medline:
18
6
2022
entrez:
3
6
2022
Statut:
epublish
Résumé
We describe the longitudinal kinetics of the serological response in COVID-19 recovered patients over a period of 14 months. The antibody kinetics in a cohort of 192 recovered patients, including 66 patients for whom follow-up serum samples were obtained at two to four clinic visits, revealed that RBD-specific antibodies decayed over the 14 months following the onset of symptoms. The decay rate was associated with the robustness of the response in that antibody levels that were initially highly elevated after the onset of symptoms subsequently decayed more rapidly. An exploration of the differences in the longitudinal kinetics between recovered patients and naïve vaccinees who had received two doses of the BNT162b2 vaccine showed a significantly faster decay in the naïve vaccinees, indicating that serological memory following natural infection is more robust than that following to vaccination. Our data highlighting the differences between serological memory induced by natural infection vs. vaccination contributed to the decision-making process in Israel regarding the necessity for a third vaccination dose.
Identifiants
pubmed: 35658051
doi: 10.1371/journal.ppat.1010569
pii: PPATHOGENS-D-21-02063
pmc: PMC9200310
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1010569Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Cell Mol Immunol. 2021 Jul;18(7):1832-1834
pubmed: 34099890
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Sci Immunol. 2020 Jun 11;5(48):
pubmed: 32527802
Nat Commun. 2021 Jul 19;12(1):4383
pubmed: 34282139
J Med Virol. 2022 Jan;94(1):388-392
pubmed: 34415572
Eur J Intern Med. 2021 Jul;89:97-103
pubmed: 34090748
Sci Rep. 2021 Feb 10;11(1):3461
pubmed: 33568715
mBio. 2020 Oct 16;11(5):
pubmed: 33067385
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Acta Biomed. 2020 Mar 19;91(1):157-160
pubmed: 32191675
N Engl J Med. 2020 Sep 10;383(11):1085-1087
pubmed: 32706954
Nature. 2021 Jul;595(7867):421-425
pubmed: 34030176
Sci Rep. 2021 Aug 18;11(1):16796
pubmed: 34408200
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Clin Transl Immunology. 2021 Mar 14;10(3):e1261
pubmed: 33747511
Clin Infect Dis. 2021 Dec 16;73(12):2366-2368
pubmed: 33693643
Lancet. 2020 Feb 15;395(10223):470-473
pubmed: 31986257
JAMA. 2020 Feb 25;323(8):709-710
pubmed: 31999307
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
J Infect Dis. 2021 Nov 16;224(9):1489-1499
pubmed: 34282461
Immunity. 2020 Nov 17;53(5):925-933.e4
pubmed: 33129373
Nat Commun. 2021 Aug 6;12(1):4740
pubmed: 34362897
Clin Immunol. 2022 Jan;234:108918
pubmed: 34971839
EBioMedicine. 2021 Sep;71:103561
pubmed: 34455390
Clin Infect Dis. 2021 Aug 2;73(3):e531-e539
pubmed: 32745196
Nat Biotechnol. 2020 Sep;38(9):1073-1078
pubmed: 32704169
J Clin Invest. 2020 Dec 1;130(12):6728-6738
pubmed: 32910806
Cell. 2019 Apr 18;177(3):524-540
pubmed: 31002794
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32229605
Sci Immunol. 2020 Oct 8;5(52):
pubmed: 33033173
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
J Infect Dis. 2021 Feb 3;223(2):197-205
pubmed: 33535236